151.02 USD
▼-5.21-3.33%
盘后 153.96 +1.95%
2026-11-19
市值
$5.28B
市盈率
—
EPS
-2.83
股息率
—
52 周区间
105.88 – 200.00
成交量
138.88K
Beta
-1.19
目标价
233.00
52W 低 105.8852W 高 200.00
价格走势
公司简介
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev...